Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11).
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Angiogenesis Inhibitors
Angiogenesis Inhibitors
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Biomarkers, Tumor
Biomarkers, Tumor
Carboplatin
Carboplatin
Confidence Intervals
Confidence Intervals
Disease-Free Survival
Disease-Free Survival
Double-Blind Method
Double-Blind Method
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Humans
Humans
Intention to Treat Analysis
Intention to Treat Analysis
Microvessels
Microvessels
Middle Aged
Middle Aged
Neuropilin-1
Neuropilin-1
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Platelet Endothelial Cell Adhesion Molecule-1
Platelet Endothelial Cell Adhesion Molecule-1
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins c-met
Retrospective Studies
Retrospective Studies
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor Receptor-2
authors with profiles
Robert S Mannel